Evidence map›Paper›PMID 31942695›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020

In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles.

Serda Kecel-Gunduz, Yasemin Budama-Kilinc, Rabia Cakir-Koc, Tolga Zorlu, Bilge Bicak, Yagmur Kokcu, Aysen E Ozel, Sevim Akyuz

Abstract read
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Serda Kecel-GunduzPhysics Department, Faculty of Science, Istanbul University, Vezneciler, 34134, Istanbul, Turkey. skecel@istanbul.edu.tr.ORCID http://orcid.org/0000-0003-0973-8223
Yasemin Budama-KilincDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yildiz Technical University, 34220, Istanbul, Turkey.
Rabia Cakir-KocDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yildiz Technical University, 34220, Istanbul, Turkey.
Tolga ZorluGraduate School of Natural and Applied Science, Yildiz Technical University, 34220, Istanbul, Turkey.
Bilge BicakPhysics Department, Faculty of Science, Istanbul University, Vezneciler, 34134, Istanbul, Turkey.
Yagmur KokcuInstitute of Graduate Studies in Sciences, Istanbul University, 34452, Istanbul, Turkey.
Aysen E OzelPhysics Department, Faculty of Science, Istanbul University, Vezneciler, 34134, Istanbul, Turkey.
Sevim AkyuzPhysics Department, Science and Letters Faculty, Istanbul Kultur University, Atakoy Campus, Bakirkoy, 34156, Istanbul, Turkey.

Funding

Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi 2423
6 · The paper itself

Abstract

backgroundArginine-vasopressin (AVP) is a neuropeptide and provides learning and memory modulation. The AVP (4-5) dipeptide corresponds to the N-terminal fragment of the major vasopressin metabolite AVP (4-9), has a neuroprotective effect and used in the treatment of Alzheimer's and Parkinson's disease.

methodsThe main objective of the present study is to evaluate the molecular mechanism of AVP (4-5) dipeptide and to develop and synthesize chitosan nanoparticle formulation using modified version of ionic gelation method, to increase drug effectiveness. For peptide loaded chitosan nanoparticles, the synthesized experiment medium was simulated for the first time by molecular dynamics method and used to determine the stability of the peptide, and the binding mechanism to protein (HSP70) was also investigated by molecular docking calculations. A potential pharmacologically features of the peptide was also characterized by ADME (Absorption, Distribution, Metabolism and Excretion) analysis. The characterization, in vitro release study, encapsulation efficiency and loading capacity of the peptide loaded chitosan nanoparticles (CS NPs) were performed by Dynamic Light Scattering (DLS), UV-vis absorption (UV), Scanning Electron Microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy techniques. Additionally, in vitro cytotoxicity of the peptide on human neuroblastoma cells (SH-SY5Y) was examined with XTT assay and the statistical analysis was evaluated.

resultsThe results showed that; hydrodynamic size, zeta potential and polydispersity index (PdI) of the peptide-loaded CS NPs were 167.6 nm, +13.2 mV, and 0.211, respectively. In vitro release study of the peptide-loaded CS NPs showed that 17.23% of the AVP (4-5)-NH2 peptide was released in the first day, while 61.13% of AVP (4-5)-NH2 peptide was released in the end of the 10th day. The encapsulation efficiency and loading capacity were 99% and 10%, respectively. According to the obtained results from XTT assay, toxicity on SHSY-5Y cells in the concentration from 0.01 μg/μL to 30 μg/μL were evaluated and no toxicity was observed. Also, neuroprotective effect was showed against H

conclusionThe experimental medium of peptide-loaded chitosan nanoparticles was created for the first time with in silico system and the stability of the peptide in this medium was carried out by molecular dynamics studies. The binding sites of the peptide with the HSP70 protein were determined by molecular docking analysis. The size and morphology of the prepared NPs capable of crossing the blood-brain barrier (BBB) were monitored using DLS and SEM analyses, and the encapsulation efficiency and loading capacity were successfully performed with UV Analysis. In vitro release studies and in vitro cytotoxicity analysis on SHSY-5Y cell lines of the peptide were conducted for the first time. Grapical abstract.

Indexed as

Arginine VasopressinChitosanNanoparticlesNeuroprotective AgentsPeptidesCell Line, TumorCell SurvivalDrug DesignHumansHydrogen PeroxideMolecular Docking SimulationMolecular Dynamics SimulationArginine VasopressinChitosanHydrogen PeroxideNeuroprotective AgentsPeptidesAVP (4–5)ChitosanDrug deliveryHsp70MDNanoparticleParkinson

Identifiers

PMID31942695
PMCPMC7214605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.